Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allogene, Biosenic, Biovie, Immunoengineering, Moderna, Mosaic Immunoengineering, Oncotelic, Signalchem, Sino Biological.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aligos, Arbele, Biocardia, Caliway, Can-Fite, Nkgen, Recce.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abeona, Astrazeneca, Averoa, Beigene, Edgewise, Immunitybio, Innocan, Medivir, Oncoc4, Revive, Tiziana.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Asklepios, Bayer, Imunon and Lumicell.
In a study from the PHOSP-COVID and ISARIC-4C consortia in the U.K., researchers have discovered inflammatory processes taking place during what is termed “long COVID.” Long COVID is defined by the World Health Organization (WHO) as the continuation or development of new symptoms for 3 or more months after the initial SARS-CoV-2 infection. It is estimated that 1 in 10 SARS-CoV-2 infections results in long COVID, thus affecting about 65 million people worldwide.
SARS-CoV-2 could proliferate in the lungs causing severe COVID-19 through a special type of immune cell. A group of scientists from Stanford University observed how this coronavirus infected interstitial macrophages through a CD209 receptor, triggering the inflammatory response observed in hospitalized patients.
Researchers at Schrodinger Inc. and Takeda Pharmaceutical Co. Ltd. have described 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Before formally introducing legislation to spur R&D of treatments for long COVID, the U.S. Senate Health, Education, Labor and Pensions Committee is calling for stakeholder input on the proposal that would require $10 billion in dedicated, mandatory NIH funding to respond to the chronic condition over the next 10 years.
Blackstone Life Sciences made an investment of up to $750 million in Moderna Inc.’s influenza program created with its mRNA technology. The new funding is designed to help propel the program forward and may help bolster a stock that has struggled in the past 12 months.
RSS
